Abstract:Certain genetic mutations lead to the development of cancer through unchecked cell growth and division. Cancer is typically treated through surgical resection, radiotherapy, and small-molecule chemotherapy. A relatively recent approach to cancer therapy involves the use of a natural process wherein small RNA molecules regulate gene expression in a pathway known as RNA interference (RNAi). RNA oligomers pair with a network of proteins to form an RNA-induced silencing complex, which inhibits the translation of mRNA into proteins, thereby controlling the expression of gene products. Synthetically produced RNA oligomers may be designed to target and silence specific oncogenes to provide cancer therapy. The primary challenges facing the use of the RNAi pathway for cancer therapy are the safe and efficacious delivery of RNA payloads and their release at pertinent sites within disease-causing cells. Nucleases are abundant in the bloodstream and intracellular environment, and therapeutic RNA sequences often require a suitable carrier to provide protection from degradation prior to reaching their site of action in the body. The use of metal core nanoparticles (NPs) serving as targeted delivery vehicles able to shield and direct RNA payloads to their intended destinations have recently gained favor. Biological barriers present in the body establish a size prerequisite for drug delivery vehicles; to overcome recognition by the body's immune system and to gain access to intracellular environments, drug carriers must be small (< 100 nm). Iron oxide and gold core NPs can be synthesized with a high degree of control to create uniform ultrasmall drug delivery vehicles capable of bypassing key biological barriers. While progress is being made in size control of liposomal and polymer NPs, such advances still lag in comparison to the exquisite tunability and time stability of size engineering achievable with metal core NPs at bulk scales. Further, unlike lipid- and viral-based transfection agents, the biodistribution of metal core NPs can be traced using noninvasive imaging techniques that capitalize on the interaction of electromagnetic radiation and the inorganic atoms at the core of the NPs. Finally, metal core NPs have been shown to match the transfection efficiency of conventional RNA-delivery vehicles while also providing less immunogenicity and minimal side effects through the addition of tumor-targeting ligands on their surface. This Account reviews recent advances in the use of iron oxide and gold NPs for RNAi therapy. An overview of the different types of RNA-based therapies is provided along with a discussion of the advantages and current limitations of the technique. We highlight design considerations for the use of iron oxide and gold NP carriers in RNAi, including a discussion of the importance of size and its role in traversing biological barriers, NP surface modifications required for targeted delivery and RNA payload release, and auxiliary properties supporting imaging functionality for treatment monitoring. Applications of NPs for combination therapies including the pairing of RNAi with chemotherapy, photothermal therapy, immunotherapy, and radiotherapy are explored through examples. Finally, future perspectives are provided with a focus on the current limitations and the potential for clinical translation of iron oxide and gold NPs in RNAi therapy.

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

RNA Nanotechnology-Mediated Cancer Immunotherapy

Nano-based delivery of RNAi in cancer therapy

Lipid Nanomaterials-Based RNA Therapy and Cancer Treatment

RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics

Unlocking the Potential of RNA Nanoparticles: A Breakthrough Approach to Overcoming Challenges in Colon Cancer Treatment

Recent Advances in RNA-Targeted Cancer Therapy

Nanoparticle‐Mediated Sirna Delivery and Multifunctional Modification Strategies for Effective Cancer Therapy

RNA nanotechnology: a new chapter in targeted therapy

Theranostic Nanoparticles for RNA-Based Cancer Treatment

Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics

RNA-Based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment

Anticancer use of nanoparticles as nucleic acid carriers

Delivery of Mrna for Cancer Therapy: Progress and Prospects

Nanovector Delivery of Sirna for Cancer Therapy

RNA therapeutics in cancer treatment

RNA Nanomedicine: Delivery Strategies and Applications

RNAi-mediated Gene Silencing in Cancer Therapy

Tumor-targeted Nano-Delivery System of Therapeutic RNA

RNA-based nanomedicines and their clinical applications

RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise